Table 1. Patient characteristics.
| Parameter | n (%) |
|---|---|
| Age (years) (median, range) | 70 (40-85) |
| Male:female | 23 (56):18 (44) |
| Myeloma type | |
| IgG | 18 (44) |
| IgA | 6 (15) |
| Light chain only | 17 (41) |
| ISS (n = 26) | |
| I | 6 (23) |
| II | 9 (35) |
| III | 11 (42) |
| R-ISS (n = 24) | |
| I | 5 (21) |
| II | 9 (38) |
| III | 10 (42) |
| FISH cytogenetics (n = 37) | |
| t(4:14) | 3 (8) |
| Del17p | 14 (39) |
| t(14:16) | 3 (8) |
| t(14:20) | 1 (3) |
| +1q21 | 16 (44) |
| −1p | 3 (8) |
| t(11:14) | 11 (31) |
| No adverse cytogenetics | 6 (17) |
| Any intermediate-/high-risk FISH | 24 (67) |
| Any high-risk FISH | 16 (44) |
| Double-hit myeloma | 11 (27) |
| Primary refractory (cohort A) | 20 (49) |
| Early relapse (cohort B) | 21 (51) |
| EMD at diagnosis (n = 36) | 18 (44) |
| Bone adjacent | 9 (22) |
| Nonbone | 9 (22) |
| Time since myeloma diagnosis (months) (median, range) | 8 (3-17.9) |
| Frailty | |
| Fit | 18 (44) |
| Intermediate fit | 9 (22) |
| Frail | 14 (34) |
| Induction regimen | |
| VCD | 20 (49) |
| VTD/VCDT | 7 (17) |
| VRD | 9 (22) |
| VD-PACE | 2 (5) |
| Othera | 3 (7) |
| Post-ASCT | 16 (39) |
ISS, international staging system; R-ISS, revised-ISS; EMD, extramedullary disease; Intermediate/high risk: t(4:14), Del17p, t(14:16), t(14:20), +1q21; double hit: >1 intermediate-/high-risk aberration; VCD, bortezomib/cyclophosphamide/dexamethasone; VTD, bortezomib/thalidomide/dexamethasone; VRD, bortezomib/lenalidomide/dexamethasone; VD-PACE, bortezomib/dexamethasone/cis-platinum/Adriamycin (doxorubicin)/cyclophosphamide/etoposide; ASCT, autologous stem cell transplant.
a
Other: bortezomib/melphalan/prednisone (n = 1), bortezomib/dexamethasone (n = 2).